Numero verde: 800-456220

High frequencies in medicine and ProNexibus Plus®: some references


High frequencies in medicine and ProNexibus Plus®: some references

Research on our high frequencies

The ProNexibus Plus® is a portable electromedical device that emits controlled radio frequencies at frequencies of 2, 4 or 8 MHz.

The device has been studied by the University of Padua and Verona and has yielded important clinical results: thanks to its anti-inflammatory, antalgic, anti-edemigenous and prorigenerative effects, the ProNexibus Plus® has been shown to be effective both in removing pain caused by osteomuscular diseases [1] (e.g., osteoarthritis of the knee, low back pain, epicondylitis, osteoarthritis of the hand, musculoskeletal injuries and trauma) and in treating chronic muscle spasticity, in patients with chronic stroke outcomes [2].

Therefore, it can be said that the delivery of high frequencies was a decisive factor in treating these patients.

ProNexibus Plus - Alte frequenze
The ProNexibus Plus® is a DEM for high-frequency diathermy treatments at 2 - 4 - 8MHz.

Other international sources on high frequencies?

1. Abe, M. et al. Multi‐institutional studies on hyperthermia using an 8‐MHz radiofrequency capacitive heating device (thermotron RF‐8) in combination with radiation for cancer therapy. 58, 7 (1986).

The first reference we find, in chronological order, dates back to. 1986 : a group of Japanese scientists developed the Thermotron RF-8 [4]. This device was developed to emit capacitive radio frequencies at the specific frequency of 8MHz: exactly like FocusMed® electromedical devices.

Without going into too much detail–at the end of the paper is the most significant bibliography from which we have drawn–the Thermotron RF-8 has been used numerous times in a variety of contexts and on numerous patients, especially in the treatment of cancer patients through hyperthermia sessions targeted at the tumor site.

The Thermotron RF-8, present since 1986, is still used today. Numerous studies using such a device, or similar devices developed by other research groups, for capacitive diathermy treatments are accumulating: experimental results are accumulating and point to an increasingly evident therapeutic role of high frequencies.

High-frequency capacitive diathermy were initially used in the field of oncology, on patients with different types of cancer: breast, cervix, liver, lung, colon. 8 MHz therapies have repeatedly been shown to be effective In increasing life expectancy[5], [6] or improve the quality of life of these patients, and as early as the 1990s, high frequencies demonstrated a significant antalgic effect [7] .

Alongside reports of the efficacy of high-frequency diathermy in cancer patients, evidence of the efficacy of high-frequency diathermy is also accumulating in the context of osteodegenerative diseases: the Thermotron RF-8 has been used, with remarkable efficacy, in the treatment of with osteoarthritis of the knee[8]. The results they obtained, in 2011, exactly overlap with those obtained by the University of Padua research group with the ProNexibus Plus ® : patients’ pain was significantly reduced with just one course of treatment, and patients recovered limb function.

In summary?

High frequencies, although little known in Italy, have a history of more than 30 years of use behind them. Over the past 30 years, they have proven to be effective in treating a great number of patients with different diseases and have also often proven to be more effective than conventional drug therapies that do not give satisfactory results especially in the long run.

Immediate adverse effects of high-frequency treatment are minimal, if not absent, and long-term complications have never been reported; therefore, it can be said that high-frequency treatment is effective and safe.

High frequencies represent a new tool available to the health care professional to be able to rapidly achieve important clinical outcomes that were previously difficult to achieve. It is only a matter of time before high frequencies become established in daily clinical practice due to their remarkable efficacy, which can be assessed by both the practitioner but, more importantly, also perceived by the patient.


[1]             S. Masiero et al, “Short-wave diathermy in the clinical management of musculoskeletal disorders: a pilot observational study,” Int J Biometeorol, Nov. 2019, doi: 10.1007/s00484-019-01806-x.

[2]             Pilot study on the clinical management of spastic equine foot: the effect of ProNexibus Plus, University of Verona, A.Picelli.

[3]             Rinovacelle for the treatment of diabetic foot ulcers, University of Salerno, B.L. Farina.

[4]          M. Abe et al, “Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (thermotron RF-8) in combination with radiation for cancer therapy,” vol. 58, no. 8, pp. 7, 1986.

[5]             M. Franckena et al, “Long-Term Improvement in Treatment Outcome After Radiotherapy and Hyperthermia in Locoregionally Advanced Cervix Cancer: An Update of the Dutch Deep Hyperthermia Trial,” International Journal of Radiation Oncology*Biology*Physics, vol. 70, no. 4, pp. 1176-1182, Mar. 2008, doi: 10.1016/j.ijrobp.2007.07.2348.

[6]             T. Ohguri et al, “Radiotherapy With 8-MHz Radiofrequency-Capacitive Regional Hyperthermia for Stage III Non-Small-Cell Lung Cancer: The Radiofrequency-Output Power Correlates With the Intraesophageal Temperature and Clinical Outcomes,” International Journal of Radiation Oncology*Biology*Physics, vol. 73, no. 1, pp. 128-135, Jan. 2009, doi: 10.1016/j.ijrobp.2008.03.059.

[7]          >T. Ohguri et al, “Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia for pain relief of unresectable and recurrent colorectal cancer,” International Journal of Hyperthermia, vol. 22, no. 1, pp. 1-14, Jan. 2006, doi: 10.1080/02656730500381152.

[8]          H. Shoji et al, “A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study,” Cancer Med, vol. 4, no. 6, pp. 834-843, Jun. 2015, doi: 10.1002/cam4.431.

[9]          K. Takahashi, K. Takenouchi, H. Nakamura, H. Kurosaki, S. Hashimoto, and T. Kamada, “The effects of radiofrequency hyperthermia on pain and function in patients with knee osteoarthritis: a preliminary report,” Journal of Orthopaedic Science, vol. 16, no. 4, pp. 376-381, Jul. 2011, doi: 10.1007/s00776-011-0093-8.

Related articles

Are you a healthcare practitioner?

Access to the display of products and information material is reserved to operators in the sector in compliance with current legislation. FocusMed Srl requires to qualify as an operator of the sector to proceed with navigation.

Legislative Decree of 24 February 1997, No 46 Article 21

1. It is forbidden to advertise to the public devices that, according to provisions adopted by decree of the Minister of Health, may be sold only on prescription or may be used with the assistance of a doctor or other healthcare professional.
2. Advertising to the public of devices other than those referred to in paragraph 1 is subject to authorization by the Ministry of Health. On the requests for authorization expresses opinion the Commission of experts provided for by article 6, paragraph 3, of the legislative decree 30 December 1992, n. 541, which for this purpose is supplemented by a representative of the Department of the Ministry of Health responsible for medical devices and one of the Ministry of Industry, Commerce and Crafts.